What's Happening?
Ionis Pharmaceuticals has presented new long-term data on DAWNZERA™ (donidalorsen) at the ACAAI 2025 Annual Meeting, demonstrating its efficacy in controlling hereditary angioedema (HAE). The data shows
a 94% reduction in HAE attack rates over one year in the OASISplus study. DAWNZERA, approved by the FDA for prophylaxis in HAE patients, offers a promising treatment option with a favorable safety profile. The presentation highlights the drug's potential to transform HAE treatment, providing valuable insights for patients and physicians.
Why It's Important?
The presentation of DAWNZERA's long-term data is significant for the HAE community, offering hope for improved disease management. The drug's efficacy and safety profile could lead to a shift in treatment paradigms, enhancing the quality of life for HAE patients. As a rare genetic condition, HAE requires effective prophylactic treatments to prevent life-threatening attacks, and DAWNZERA's approval and data support its role in addressing this need.
What's Next?
Ionis will continue to present data and insights at the ACAAI meeting, contributing to informed treatment decisions for HAE patients. The company's focus on RNA-targeted therapies and gene editing may lead to further advancements in treating rare diseases. The ongoing research and development efforts could expand DAWNZERA's application and influence future therapeutic approaches in the field.
